Key Highlights
- 13.98% is the indicated pre-market decline for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) on November 17, 2026, taking the price to USD 1.60 from a calculated prior close of USD 1.86, a calculated move of negative USD 0.26.
- 11.3 million USD was the second quarter 2026 net loss on Revenue of USD 239,000 from laboratory services plus USD 21,000 from research-use-only kits, with a gross Margin of 65.7% on Gross Profit of USD 157,000.
- 18.7 million USD was cash, cash equivalents and restricted cash at June 30, 2026, against an accumulated Deficit of USD 416.3 million and an adjusted EBITDA loss of USD 7.8 million for the quarter.
- 3 is the quarter covered by the results the company scheduled for November 16, 2026, one session before the November 17, 2026 pre-market decline, though no figures from that release were found in published coverage.
What Moved Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) in Pre-Market Trading on November 17, 2026 (-USD 0.26, -13.98%)
The indicated pre-market price for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is USD 1.60 on November 17, 2026, a pre-market move of -13.98%. The calculated prior close is USD 1.86 (USD 1.60 divided by 0.8602) and the calculated USD move is negative USD 0.26. Using 32.72 million shares outstanding from published market data, the calculated Market Value at the indicated price is about USD 52.35 million, down from USD 92.61 million when the price was USD 2.83 on October 23, 2026. Pre-market Volume figures were not found.
The Rationale: Third Quarter Results Timing and FDA Review for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX)
The company scheduled the release of its third quarter results for November 16, 2026. The specific figures from that release were not found in published coverage, so no link between those results and the pre-market move can be stated. The company's GraftAssureDx kit is under FDA review, the agency has requested additional information, and management targets Marketing authorization later in 2026, subject to agency timing. A February 2026 registered direct offering raised USD 26.0 million gross, or USD 24.6 million net, including Investment from Bio-Rad.
Valuation, Liquidity and Risks for Insight Molecular Diagnostics Inc. (NASDAQ:IMDX)
Second quarter 2026 operating expenses were USD 11.6 million, including a USD 2.3 million non-cash loss from contingent consideration and USD 661,000 of stock-based compensation. Published market data show a trailing net loss of USD 49.36 million, Operating Cash Flow of negative USD 27.08 million, total Debt of USD 2.63 million and negative shareholders' Equity of USD 21.30 million. Management believes cash is sufficient for at least twelve months. At a calculated market value near USD 52.35 million, the shares carry small-cap volatility, financing, dilution and regulatory timing risk.
Where Things Stand
Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is indicated down 13.98% in pre-market trading on November 17, 2026, at USD 1.60, a calculated USD 0.26 below a calculated prior close of USD 1.86. The company scheduled third quarter results for November 16, 2026, but no figures were found. Second quarter 2026 revenue was USD 260,000 in total, with a net loss of USD 11.3 million and cash of USD 18.7 million. Management expects revenue to shift toward kit sales after FDA authorization, which is not guaranteed. Pre-market moves can reverse at the open, and this article is not investment advice.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...